We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Nanobiochip Diagnoses Heart Attacks

By HospiMedica International staff writers
Posted on 12 May 2010
A diagnostic tool developed by scientists to detect heart attacks using a person's saliva is being tested in human trials.

A microchip sensor, the nanobiochip, processes the saliva and yields on-the-spot results. More...
To obtain a saliva sample for the device, health care providers swab a patient's gums with a cotton-tipped stick. The saliva is transferred to the disposable diagnostic microchip. The microchip is then inserted into an analyzer and within a few minutes the saliva sample is checked and results delivered.

Nanobiochips deliver all the capabilities of a traditional laboratory but do not require expensive instrumentation to get results. Manufactured with techniques pioneered by the microelectronics industry, they are able to analyze large amounts of biomarker data at significantly lower cost than traditional tests.

The nanobiochip was developed at Rice University (Houston, TX, USA). It is being tested in human trials at the Michael E. DeBakey VA Medical Center (MEDVAMC; Houston, TX, USA) in collaboration with Baylor College of Medicine (BCM; Houston, TX, USA). Over the next two years, samples from approximately 500 patients who come to the MEDVAMC emergency room with chest pain or heart attack-related symptoms will be collected for the trial.

"We find salivary tests, when combined with electrocardiograms (ECGs), can provide more accurate information than the ECG alone for patients with chest pain," John T. McDevitt, professor of chemistry and bioengineering at Rice said. "Saliva-based tests have the potential to quickly diagnose heart-attack victims as well as to find false alarms."

Chest pain brings about 5 million patients to U.S. emergency rooms each year, but 80 % of those patients are not suffering heart attacks. Blood test results can take anywhere from 90 minutes to three hours, and in many cases it may be 12 to 24 hours before patients know whether or not they had a heart attack.

Prof. McDevitt said that the new test could save lives, time, and money by allowing doctors to identify those suffering from a heart attack before administering a battery of costly tests.

Related Links:

Rice University
Michael E. DeBakey VA Medical Center
Baylor College of Medicine



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.